Literature DB >> 15870390

Role of N-terminal amino acids in the absorption-enhancing effects of the c-terminal fragment of Clostridium perfringens enterotoxin.

Akane Masuyama1, Masuo Kondoh, Hirotoshi Seguchi, Azusa Takahashi, Motoki Harada, Makiko Fujii, Hiroyuki Mizuguchi, Yasuhiko Horiguchi, Yoshiteru Watanabe.   

Abstract

We recently found that a polypeptide, the C-terminal of Clostridium perfringens enterotoxin (C-CPE), was a novel type of drug absorption enhancer. The C-terminal of C-CPE is thought to play a role in the binding of C-CPE to its receptor, claudin-4; however, the function of the N-terminal of C-CPE is unclear. In the present study, we evaluated the role of the N-terminal domain of C-CPE in jejunal absorption and claudin-4 binding. The treatment of rat jejunum with C-CPE resulted in enhanced absorption of dextran, with a molecular weight of 4000 Da. However, treatment with C-CPE220, which lacks the 36 N-terminal amino acids of C-CPE, did not enhance jejunal absorption. C-CPE had affinity for claudin-4 in rat jejunum lysates and Caco-2 lysates, but C-CPE220 did not. Interaction of C-CPE with the recombinant extracellular domain 2 of human claudin-4 (EC2hCld-4), which is the putative binding site for C-CPE, was observed, but C-CPE220 had no affinity for EC2hCld-4. To investigate the effect of C-CPE220 on the barrier function of tight junctions, we measured transepithelial electric resistance (TER) in C-CPE- or C-CPE220-treated Caco-2 monolayer cells. Although C-CPE decreased TER in Caco-2 monolayer cells, C-CPE220 did not disrupt the barrier function of tight junctions. Together, these results indicate that the 36 N-terminal amino acids of C-CPE may be necessary for the enhanced absorption mediated by C-CPE and play a partial role in binding to claudin-4.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15870390     DOI: 10.1124/jpet.105.085399

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Noncytotoxic Clostridium perfringens enterotoxin (CPE) variants localize CPE intestinal binding and demonstrate a relationship between CPE-induced cytotoxicity and enterotoxicity.

Authors:  James G Smedley; Juliann Saputo; Jacquelyn C Parker; Mariano E Fernandez-Miyakawa; Susan L Robertson; Bruce A McClane; Francisco A Uzal
Journal:  Infect Immun       Date:  2008-05-27       Impact factor: 3.441

Review 2.  Animal models to study the pathogenesis of enterotoxigenic Clostridium perfringens infections.

Authors:  Francisco A Uzal; Bruce A McClane
Journal:  Microbes Infect       Date:  2012-06-17       Impact factor: 2.700

3.  Molecular determinants of the interaction between Clostridium perfringens enterotoxin fragments and claudin-3.

Authors:  Lars Winkler; Claudia Gehring; Ariane Wenzel; Sebastian L Müller; Christian Piehl; Gerd Krause; Ingolf E Blasig; Jörg Piontek
Journal:  J Biol Chem       Date:  2009-05-08       Impact factor: 5.157

4.  In-silico design and production of a novel antigenic chimeric Shigella IpaB fused to C-terminal of Clostridium perfringens enterotoxin.

Authors:  Sina Arabshahi; Abdollah Derakhshandeh; Bahar Nayeri Fasaei; Aytak Novinrooz
Journal:  Mol Biol Rep       Date:  2019-08-31       Impact factor: 2.316

5.  In silico design of a novel chimeric shigella IpaB fused to C terminal of clostridium perfringens enterotoxin as a vaccine candidate.

Authors:  Sina Arabshahi; Bahar Nayeri Fasaei; Abdollah Derakhshandeh; Aytak Novinrooz
Journal:  Bioengineered       Date:  2017-11-30       Impact factor: 3.269

6.  Structural constraints for the binding of short peptides to claudin-4 revealed by surface plasmon resonance.

Authors:  Jun Ling; Hailing Liao; Robin Clark; Mandy Sze Man Wong; David D Lo
Journal:  J Biol Chem       Date:  2008-09-09       Impact factor: 5.157

7.  Claudin-4 binder C-CPE 194 enhances effects of anticancer agents on pancreatic cancer cell lines via a MAPK pathway.

Authors:  Tsuyoshi Kono; Masuo Kondoh; Daisuke Kyuno; Tatsuya Ito; Yasutoshi Kimura; Masafumi Imamura; Takayuki Kohno; Takumi Konno; Tomohisa Furuhata; Norimasa Sawada; Koichi Hirata; Takashi Kojima
Journal:  Pharmacol Res Perspect       Date:  2015-12-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.